Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma

Experimental Dermatology

Volumn 20, Issue 5, 2011, Pages 430-434

  Knol, Anne C ^a   Nguyen, Jean M ^a,c   Quéreux, Gaëlle ^a,b   Brocard, Anabelle ^b   Khammari, Amir ^a,b   Dréno, Brigitte ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c CHU DE NANTES   (France)

Author keywords

Adoptive immunotherapy; Malignant melanoma; Nuclear Forkhead Box Transcription Factor Foxp3; Tumor infiltrating lymphocytes

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD4; DISEASE-FREE SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 79954621235     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2011.01260.x     Document Type: Article

References (30)

1. Jotereau F, Labarriere N, Gervois N et al. Bull Cancer 2003: 90: 583-586.
2. Jotereau F, Pandolfino M C, Boudart D et al. J Immunother 1991: 10: 405-411.
3. Fujisawa Y, Nabekura T, Nakao T et al. Exp Dermatol 2009: 18: 396-403.
4. Terabe M, Berzofsky J A. Curr Opin Immunol 2004: 16: 157-162.
5. Somasundaram R, Jacob L, Swoboda R et al. Cancer Res 2002: 62: 5267-5272.
6. Javia L R, Rosenberg S A. J Immunother 2003: 26: 85-93.
7. Liyanage U K, Moore T T, Joo H G et al. J Immunol 2002: 169: 2756-2761.
8. Shevach E M. Nat Rev Immunol 2002: 2: 389-400.
9. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunol Rev 2001: 182: 18-32.
10. Shevach E M, McHugh R S, Piccirillo C A et al. Immunol Rev 2001: 182: 58-67.
11. Hori S, Nomura T, Sakaguchi S. Science 2003: 299: 1057-1061.
12. Fontenot J D, Gavin M A, Rudensky A Y. Nat Immunol 2003: 4: 330-336.
13. Khattri R, Cox T, Yasayko S A et al. Nat Immunol 2003: 4: 337-342.
14. Salama P, Phillips M, Grieu F et al. J Clin Oncol 2009: 27: 186-192.
15. Badoual C, Hans S, Rodriguez J et al. Clin Cancer Res 2006: 12: 465-472.
16. Gao Q, Qiu S J, Fan J et al. J Clin Oncol 2007: 25: 2586-2593.
17. Curiel T J, Coukos G, Zou L et al. Nat Med 2004: 10: 942-949.
18. Sato E, Olson S H, Ahn J et al. Proc Natl Acad Sci USA 2005: 102: 18538-18543.
19. Wolf D, Wolf A M, Rumpold H et al. Clin Cancer Res 2005: 11: 8326-8331.
20. Ahmadzadeh M, Felipe-Silva A, Heemskerk B et al. Blood 2008: 112: 4953-4960.
21. Viguier M, Lemaitre F, Verola O et al. J Immunol 2004: 173: 1444-1453.
22. Pfaffl M W. Nucleic Acids Res 2001: 29: e45.
23. Mourmouras V, Fimiani M, Rubegni P et al. Br J Dermatol 2007: 157: 531-539.
24. De Panfilis G, Campanini N, Santini M et al. J Invest Dermatol 2008: 128: 676-684.
25. Miracco C, Mourmouras V, Biagioli M et al. Oncol Rep 2007: 18: 1115-1122.
26. Hillen F, Baeten C I, van de Winkel A et al. Cancer Immunol Immunother 2008: 57: 97-106.
27. Ladanyi A, Mohos A, Somlai B et al. Pathol Oncol Res 2010: 16: 303-309.
28. Correll A, Tuettenberg A, Becker C et al. Exp Dermatol 2010: 19: e213-e221.
29. Wieczorek G, Asemissen A, Model F et al. Cancer Res 2009: 69: 599-608.
30. Janson P C, Winerdal M E, Marits P et al. PLoS ONE 2008: 3: e1612.